NCT04745689
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT04745689
Title Study of AZD2811 + Durvalumab in ES-SCLC (TAZMAN)
Acronym TAZMAN
Recruitment Active, not recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors AstraZeneca
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | POL | ESP

Facility Status City State Zip Country Details
Research Site Grand Rapids Michigan 49503 United States Details
Research Site Bydgoszcz 85-796 Poland Details
Research Site Olsztyn 10-357 Poland Details
Research Site Poznan 60-693 Poland Details
Research Site Cheongju-si 28644 South Korea Details
Research Site Jinju 52727 South Korea Details
Research Site Seoul 03722 South Korea Details
Research Site Seoul 05505 South Korea Details
Research Site Seoul 06351 South Korea Details
Research Site Seoul 06591 South Korea Details
Research Site Seville 41071 Spain Details
Research Site Valencia 46015 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field